Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 68.3 mg (equivalent: atomoxetine, qty 60 mg) - capsule, hard - excipient ingredients: gelatin; indigo carmine; titanium dioxide; pregelatinised maize starch; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 45.5 mg (equivalent: atomoxetine, qty 40 mg) - capsule, hard - excipient ingredients: gelatin; pregelatinised maize starch; iron oxide yellow; indigo carmine; titanium dioxide; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 28.5 mg (equivalent: atomoxetine, qty 25 mg) - capsule, hard - excipient ingredients: iron oxide yellow; gelatin; titanium dioxide; pregelatinised maize starch; indigo carmine; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 20.5 mg (equivalent: atomoxetine, qty 18 mg) - capsule, hard - excipient ingredients: iron oxide yellow; pregelatinised maize starch; gelatin; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 11.4 mg (equivalent: atomoxetine, qty 10 mg) - capsule, hard - excipient ingredients: gelatin; titanium dioxide; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - nitrofurantoin, quantity: 100 mg - capsule, hard - excipient ingredients: purified talc; magnesium stearate; lactose monohydrate; pregelatinised maize starch; titanium dioxide; sunset yellow fcf; purified water; quinoline yellow; gelatin - treatment of urinary tract infections such as cystitis and pyelitis when due to susceptible pathogens. nitrofurantoin does not reach effective levels in plasma and consequently is not indicated for cortical or perinephric abscesses and in cases of prostatitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - nitrofurantoin, quantity: 100 mg - capsule, hard - excipient ingredients: magnesium stearate; lactose monohydrate; purified talc; pregelatinised maize starch; titanium dioxide; sunset yellow fcf; purified water; quinoline yellow; gelatin - treatment of urinary tract infections such as cystitis and pyelitis when due to susceptible pathogens. nitrofurantoin does not reach effective levels in plasma and consequently is not indicated for cortical or perinephric abscesses and in cases of prostatitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - nitrofurantoin, quantity: 50 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; magnesium stearate; purified talc; lactose monohydrate; titanium dioxide; sunset yellow fcf; purified water; quinoline yellow; gelatin - treatment of urinary tract infections such as cystitis and pyelitis when due to susceptible pathogens. nitrofurantoin does not reach effective levels in plasma and consequently is not indicated for cortical or perinephric abscesses and in cases of prostatitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - nitrofurantoin, quantity: 50 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; purified talc; magnesium stearate; lactose monohydrate; titanium dioxide; sunset yellow fcf; purified water; quinoline yellow; gelatin - treatment of urinary tract infections such as cystitis and pyelitis when due to susceptible pathogens. nitrofurantoin does not reach effective levels in plasma and consequently is not indicated for cortical or perinephric abscesses and in cases of prostatitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - nitrofurantoin, quantity: 100 mg - capsule, hard - excipient ingredients: purified talc; lactose monohydrate; magnesium stearate; pregelatinised maize starch; titanium dioxide; sunset yellow fcf; purified water; quinoline yellow; gelatin - treatment of urinary tract infections such as cystitis and pyelitis when due to susceptible pathogens. nitrofurantoin does not reach effective levels in plasma and consequently is not indicated for cortical or perinephric abscesses and in cases of prostatitis.